Inhibition of choroidal neovascularization
US9121019B2 · kind B2 · utility
Assignee
Inventor
Key dates
| Filing date | Jun 14, 2013 |
| Grant date | Sep 1, 2015 |
| Priority date | — |
| Expiry date | Dec 10, 2033 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2502/11
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Methods of treatment of diseases that include or are characterized by inappropriate or pathological neovascularization are disclosed. These diseases include diseases of the eye, such as diabetic retinopathy, retinopathy of prematurity, and choroidal neovascularization which can occur in age-related macular degeneration (AMD). Disclosed methods include administering agents that cause directly or indirectly upregulation of the ABCA1 transporter protein in macrophages. These agents include, without limitation, LXR agonists. In some embodiments, inhibitors of CETP expression or activity can also be effective. Administration routes can include, without limitation, intraocular, periocular, or systemic administration.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.